Tumor_Target_Symbols,Mutation,Tumor_Target_Aliases,Tumor_Target_Ensembl_Gene_IDs,Antigen_Category,HLA_Restriction,TCR_origin,Genetic_Modification_System,Affinity,Sponsor,Product,Disease,Recruitment,ORR,Responses,Duration time,Toxicity,Dose,Trial,Reference,Recruitment 1×10^8,ORR 1×10^8,Response 1×10^8,Recruitment 5×10^8,ORR 5×10^8,Response 5×10^8,Recruitment 1×10^9,ORR 1×10^9,Response 1×10^9,Recruitment 5×10^9,ORR 5×10^9,Response 5×10^9,Recruitment 1×10^10,ORR 1×10^10,Response 1×10^10,Recruitment 5×10^10,ORR 5×10^10,Response 5×10^10,Recruitment 1×10^11,ORR 1×10^11,Response 1×10^11
MART-1,,MLANA,ENSG00000120215,TAA - differentation,A*02:01,Human natural TCR,Retroviral,Medium,"NCI, Rosenberg",DMF5,melanoma,20,30,"6/20, 30% (ORR/PR)",——,Skin toxicity (14 pts);Uveitis (12 pts);Hearing loss (10 pts),5×10^8-3×10^11/person,NCT00509288,"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. (2009) 114:535–46. doi: 10.1182/blood-2009-03-211714",0,0,_,0,0,_,3,0,_,5,40%,2,3,33%,1,3,67%,2,0,0,_
gp100,,PMEL,ENSG00000185664,TAA - differentation,A*02:01,mice natural TCR, lentiviral,High,"NCI, Rosenberg",gp100(154),melanoma,16,18.8,"3/16, 18.8% (ORR) 1/16 (CR), 2/16 (PR)",____,Skin toxicity (15 pts);Uveitis (4 pts);Hearing loss (5 pts),1.8×10^9-1.1×10^11/person,NCT00509496,"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. (2009) 114:535–46. doi: 10.1182/blood-2009-03-211714",_,_,_,_,_,_,3,0,0,3,0,0,2,0,0,4,50%,2,2,0.5,1
MART-1,,MLANA,ENSG00000120215,TAA - differentation,A*02:01,Human natural TCR,Retroviral,Low,"NCI, Rosenberg",DMF4,melanoma,17,12,"2/17, 12% (ORR/PR)，1/17 (MR)",21months,None ,1.0×10^9-86×10^9/person,NS,"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science (2006) 314:126–9. doi: 10.1126/SCIENCE.1129003",_,_,_,_,_,_,2,50%,1,4,0,0,0,0,0,0,0,0,1,100%,1
MART-1,,MLANA,ENSG00000120215,TAA - differentation,A*02:01,Human,Retroviral,Medium,"UCLA, Antoni Ribas",DMF5,melanoma,13,69,9 of 13 treated patients (69%) showed evidence of tumor regression,——,Erythematous skin rash (3 pts); Acute respiratory distress (2 pts), 1×10^9-1×10^10/person,NCT00910650,"Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, et al. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients With Metastatic Melanoma. Clin Cancer Res (2014) 20:2457–65. doi: 10.1158/1078-0432.CCR-13-3017",,,,,,,,,,,,,,,,,,,,,
CEACAM5,,CEA,ENSG00000105388,TAA - differentation,A*02:01,mice,Retroviral,High,NCI,,colorectal cancer,3,33.3,"1/3, 33.3% (ORR/PR)",——,Severe colitis (3 pts),2–4 × 10^8/person,NCT00923806,"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. (2011) 19:620–6. doi: 10.1038/mt.2010.272",2,50%,1,1,0,0,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_
WT1,,,ENSG00000184937,TAA - overexpression,A*02:01,Human,Retroviral,High,_,_,acute leukemia/myelodysplastic syndrome,8,37.5,3/8pts(PR), survived more than 12 months,None,2×10^8-5×10^9/person,NCT02550535,"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and persistence ofWT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. (2017) 130:1985–94. doi: 10.1182/blood-2017-06-791202",3,67%,2,2,0,0,4,25%,1,_,_,_,_,_,_,_,_,_,_,_,_
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human enhanced TCR,Retroviral,High,ADAP & NCI,C259 TCR,melanoma,20,55,"11/20, 55% (ORR) 4/20 CR, 7/20 PR",>1year,None,1.6×10^10-1.3×10^11/person,NCT00670748,"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A Pilot Trial Using Lymphocytes Genetically Engineered With an NYESO-1–Reactive T-Cell Receptor: Long-Term Follow-Up and Correlates With Response. Clin Cancer Res (2015) 21:1019–27. doi: 10.1158/1078-0432.CCR-14-2708",_,_,_,_,_,_,_,_,_,0,0,0,2,0,0,7,71%,5,3,100%,3
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human enhanced TCR,Retroviral,High,ADAP & NCI,C259 TCR,synovial sarcoma,18,61.1,"11/18, 61.1% (ORR) 1/18 CR, 10/18 PR",>1year,None,1.6×10^10-1.3×10^11/person,NCT00670748,"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A Pilot Trial Using Lymphocytes Genetically Engineered With an NYESO-1–Reactive T-Cell Receptor: Long-Term Follow-Up and Correlates With Response. Clin Cancer Res (2015) 21:1019–27. doi: 10.1158/1078-0432.CCR-14-2708",_,_,_,_,_,_,_,_,_,_,_,_,1,0,0,5,60%,3,3,33%,1
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01;A*02:06,Human enhanced TCR,Retroviral,High,"Mile University, Tsu Japan",TBI-1301,various solid tumors,9,33.3,"3/9, 33.3% (ORR/PR)",40months,CRS (3 pts),5×10^8-5×10^9/person,NCT02366546,"Ishihara M, Kitano S, Hattori H, Miyahara Y, Kato H, Mishima H, et al. Tumor Responses and Early Onset Cytokine Release Syndrome in Synovial Sarcoma Patients Treated With a Novel Affinity-Enhanced NY-ESO-1- Targeting TCR-Redirected T Cell Transfer [Conference presentation]. Am Soc Clin Oncol (2019) 530. doi: 10.1200/JCO.2019.37.15_SUPPL.2530",_,_,_,3,0,0,_,_,_,6,50%,3,_,_,_,_,_,_,_,_,_
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human,Retroviral,High avidity,JCCC&NCI,,various solid tumors,10,20,"2/10, 20% (ORR) 1/10 (CR), 1/10 (PR), 4/10 (tR)",Up to 6 years,Neutropenia;fever;pancytopenia;increased blood pressure,7.7×10^8-1×10^9/person,NCT01697527/NCT02070406,"Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang R, Wang X, Tsoi J, et al. A Pilot Trial of the Combination of Transgenic NY-ESO-1-Reactive Adoptive Cellular Therapy With Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res (2019) 25:2096–108. doi: 10.1158/1078-0432.CCR-18-3496",,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01;A*02:06,Human enhanced TCR,Retroviral,Affinity enhanced,University Health Network,TBI-1301,various solid tumors,9,22.2,"2/9, 22.2% (ORR/PR) 5/9 (SD)",3.6-10.5months,CRS grade 1-2 (5 pts),5×10^9 cells,NCT02869217,"Butler MO, Sotov V, Saibil S, Bonilla L, Boross-Harmer S, Fyrsta M, et al. Adoptive T Cell Therapy With TBI-1301 Results in Gene-Engineered T Cell Persistence and Anti-Tumour Responses in Patients With NY-ESO-1 Expressing Solid Tumours. Ann Oncol (2019) 30:v481. doi: 10.1093/ANNONC/MDZ253.009",_,_,_,_,_,_,1,0,0,8,25%,2,_,_,_,_,_,_,_,_,_
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01 ,Human enhanced TCR, lentiviral,High,ADAP,C259 TCR,synovial sarcoma,42,35.7,"15/42, 35.7% (ORR) 1/42 (CR), 14/42 (PR), 24/42 (SD)",a median duration of response (DOR) of 30.9 weeks (range 13.6–72.1 weeks),CRS grades 1 (2 pts)/2 (1 pts)/3 (2 pts), 0.45–14.4 × 10^9/person,NCT01343043,"Ramachandran I, Lowther D, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, et al. Systemic and Local Immunity Following Adoptive Transfer of NY-ESO-1 SPEAR T Cells in Synovial Sarcoma. J Immunother Cancer (2019) 7:276. doi: 10.1186/S40425-019-0762-2",,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01 ,Human, lentiviral,——,University of Pennsylvania,,multiple myeloma;MRCLS,3,0,"0/3, 0% (ORR) 2/3 (SD)",persisted for up to 9 months,None,6.0 × 10^7-7.1 × 10^8/kg/person,NCT03399448,"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-Engineered T Cells in Patients With Refractory Cancer. Science (2020) 367:eaba7365. doi: 10.1126/SCIENCE.ABA7365",3,0,0,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human enhanced TCR, lentiviral,High,Pennsylvania,C259 TCR,multiple myeloma (Post-HSCT),25,84,"21/25, 84% (ORR) 2/25 (sCR), 1/25 (CR), 13/25 (VGPR), 5/25 (PR), 4/25 (SD)","Median progression-free survival was 13.5 months (range, 3.2-60.6 months); median overall survival was 35.1 months (range, 6.4-66.7 months).",GVHD (6 pts). Likely not related to the engineered TCR; Rash in 3 patients; diarrhea in 2 patients; hypotension in 1 patient,1×10^10/person,NCT01350401;NCT01352286,"Ramachandran I, Lowther D, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, et al. Systemic and Local Immunity Following Adoptive Transfer of NY-ESO-1 SPEAR T Cells in Synovial Sarcoma. J Immunother Cancer (2019) 7:276. doi: 10.1186/S40425-019-0762-2",_,_,_,_,_,_,_,_,_,_,_,_,25,84%,21,_,_,_,_,_,_
MAGE-A3,,,ENSG00000221867,TAA - CT,A*01,mice natural TCR,Retroviral,a moderately high-affinity TCR,Washington University;The University of Pennsylvania,MAGE-A3a3a,Metastatic melanoma;multiple myeloma,2,0,0/2CR or PR,none,2 died for cardiac toxicity,2.4–5.3 × 10^9/person,NCT01350401 and NCT01352286,"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma. Blood (2013) 122:863–71. doi: 10.1182/BLOOD-2013-03-490565",_,_,_,_,_,_,_,_,_,2,0,0,_,_,_,_,_,_,_,_,_
MAGE-A3;MAGE-A12,,,ENSG00000221867;ENSG00000213401,TAA - CT,A*01,mice natural TCR,Retroviral,High,NCI,_,various solid tumors,9,55.6,"5/9, 55.6% (ORR) 1/9 (CR), 4/9 (PR)",15months,Neurological toxicity (3 pts); 2 pt deaths.,28–79 ×10^9/person,NCT01273181,"Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z, et al. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. J Immunother (2013) 36:133–51. doi: 10.1097/CJI.0B013E3182829903",_,_,_,_,_,_,4,50%,2,5,60%,3,_,_,_,_,_,_,_,_,_
MAGE-A3,,,ENSG00000221867,TAA - CT,DPB1*04:01,Human natural TCR,Retroviral,Medium,"NCI, Rosenberg",,"Cervical cancer, kidney cancer, urothelial cancer, melanoma, breast cancer",17,23.5,"4/17, 23.5% (ORR) 1/17 (CR), 3/17 (PR)",>29months,Fever (10 pts); elevated ALT/AST/creatinine (2 pts),0.78 - 1.23 × 10^11/person,NCT02111850,"Lu Y, Parker L, Lu T, Zheng Z, Toomey M, White D, et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol (2017) 35:3322–9. doi: 10.1200/JCO.2017.74.5463",2,0,0,_,_,_,2,50%,1,_,_,_,2,0,0,1,0,0,8,37.50%,3
MAGE-A3,,,ENSG00000221867,TAA - CT,A*01,Human,Retroviral,High avidity,,,"various solid tumors，Breast, cervical, kidney, melanoma, bladder cancer",2,50,1/2pts(PR),——,Grade 3 diarrhea; Grade 3 intestinal obstruction; Grade 3 atrial fibrillation; Grade 3 acute kidney injury; Grade 4 hemophagocytic syndrome,1×10^8-1×10^9/person,NCT02153905,"Morgan, R. A., Dudley, M. E., Yu, Y. Y., Zheng, Z., Robbins, P. F., Theoret, M. R., Wunderlich, J. R., Hughes, M. S., Restifo, N. P., & Rosenberg, S. A. (2003). High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Journal of immunology (Baltimore, Md. : 1950), 171(6), 3287–3295. https://doi.org/10.4049/jimmunol.171.6.3287",,,,,,,,,,_,_,_,_,_,_,_,_,_,_,_,_
MAGE-A4,,,ENSG00000147381,TAA - CT,A*02,Human enhanced TCR, lentiviral,High,ADAP,ADP-A2M4 SPEAR T cells,various solid tumors,38,23.7,"9/38, 23.7%(ORR/PR) 18/38 (SD)",Median duration of response in these patients was 28 weeks and median progression-free survival was 20 weeks,2 pt related deaths (aplastic anemia and CVA) - not likely off target toxicity,1.2 ×10^9 - 10×10^9/person,NCT03132922,"Hong DS, Van Tine BA, Olszanski AJ, Johnson ML, Liebner DA, Trivedi T, et al. Phase I Dose Escalation and Expansion Trial to Assess the Safety and Efficacy of ADP-A2M4 SPEAR T Cells in Advanced Solid Tumors[Conference Presentation]. In: 2020 ASCO Annual Meeting (American Society of Clinical Oncology). Journal of Clinical Immunology (2020) p.102. doi: 10.1200/JCO.2020.38.15_SUPPL.102",_,_,_,_,_,_,,,,,,,_,_,_,_,_,_,_,_,_
MAGE-A4,,,ENSG00000147381,TAA - CT,A*02,Human enhanced TCR, lentiviral,High,ADAP, ADPA2M4CD8,various solid tumors,5,40,"2/5, 40% (ORR/PR) 3/5 (SD)",progression-free survival >6 months,No DLTs or SAEs,1-10×10^9/person,NCT04044859,"Hong D, Clarke J, Johanns T, Kebriaei P, Heymach J, Galal A, et al. Initial Safety, Efficacy, and Product Attributes From the SURPASS Trial With ADPA2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8a Co-Receptor [Conference Presentation]. In: SITC 2020 (BMJ Specialist Journals). Journal for ImmunoTherapy of Cancer (2020) p. A231. doi: 10.1136/JITC-2020-SITC2020.0379",_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,5,40%,2
MAGE-A4,,,ENSG00000147381,TAA - CT,A*02,Human enhanced TCR, lentiviral,High,ADAP,ADP-A2M4 SPEAR T cells,synovial sarcoma,59,40.7,"24/59, 40.7% (ORR) 2/59 (PR), 22/59 (CR), 15/33 (SD)","Responders, median PFS 58.3 weeks; Non-responders (red), median PFS 12.0 weeks.",CRS grades 1-2 (21 pts)/3 (1pt),1×10^9 - 10×10^9/person,NCT04044768,"Identification of Response Stratification Factors from Pooled Efficacy Analyses of Afamitresgene Autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in Metastatic Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Phase 1 and Phase 2 Trials. American Society of Clinical Oncology (ASCO). June 3-7 2022. Sandra P. D’Angelo, MD, et al.",_,_,_,_,_,_,,,,,,,,,,_,_,_,_,_,_
MAGE-A4,,,ENSG00000147381,TAA - CT,A*02,Human enhanced TCR, lentiviral,High,ADAP,ADP-A2M4 SPEAR T cells,MRCLS,10,10,"1/10, 10% (ORR) 1/10 (PR)","Responders, median PFS 58.3 weeks; Non-responders (red), median PFS 12.0 weeks.",CRS grades 1-2 (21 pts)/3 (1pt),1×10^9 - 10×10^9/person,NCT04044768,"Identification of Response Stratification Factors from Pooled Efficacy Analyses of Afamitresgene Autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in Metastatic Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Phase 1 and Phase 2 Trials. American Society of Clinical Oncology (ASCO). June 3-7 2022. Sandra P. D’Angelo, MD, et al.",_,_,_,_,_,_,,,,,,,,,,_,_,_,_,_,_
MAGE-A4,,,ENSG00000147381,TAA - CT,A*24:02,Human natural TCR,Retroviral,Medium,Mie University,,esophageal cancer,10,0,"0/10, 0% (ORR/PR) 3/10 SD","a median of 9 months (range, 3–15 months)",None,2×10^8-5×10^9/person,UMIN000002395,"Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res.(2015) 21:2268–77. doi: 10.1158/1078-0432.CCR-14-1559",3,0,0,_,_,_,4,0,0,3,0,0,_,_,_,_,_,_,_,_,_
MAGE-A10,,,ENSG00000124260 ,TAA - CT,A*02,Human enhanced TCR, lentiviral,High,ADAP,ADP-A2M10,"Urothelial carcinoma, head and neck cancer, melanoma, bladder urothelial carcinoma，various solid tumors",8,0,"0/8, 0% (ORR/PR)",up to 15 years,CRS (1 pt),group 1: 0.08 × 109 - 0.12 × 109 cells; group 2: 0.5×10^9 - 1.2×10^9 cells; and group 3: >1.2×10^9 - 6.0×10^9 cells.,NCT02989064 NCT02592577,"Lam VK, Hong DS, Heymach J, Blumenschein GR, Creelan BC, Bradbury PA, et al. Initial Safety Assessment of MAGE-A10c796TCR T-Cells in Two Clinical Trials [Conference presentation]. Am Soc Clin Oncol (2018) 3056.doi: 10.1200/JCO.2018.36.15_SUPPL.3056",_,_,_,_,_,_,4,0,0,4,0,0,_,_,_,_,_,_,_,_,_
HPV E6,,,,Viral - HPV,A*02:01,Human natural TCR,Retroviral,Medium,NCI & Kite,E6 TCR  ,HPV-associated solid cancers,12,16.7,"2/12, 16.7% (ORR/PR) 4/12 (SD)",——,None,1×10^9-1×170^9/person,NCT02280811,"Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. T cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-In-Human, Phase I/II Study. J Clin Oncol (2019) 37:2759–68. doi: 10.1200/JCO.18.02424",_,_,_,_,_,_,1,0,0,_,_,_,1,0,0,0,0,0,9,22%,2
HPV E7,,,,Viral - HPV,A*02:01 ,Human natural TCR,Retroviral,High,NCI & Kite,E7 TCR,HPV-associated carcinomas,12,50,"6/12, 50% (ORR/PR) 4/12 (SD)",10 months,"1 DLT, not likely off target toxicity",1×10^9-1.2×10^11/person,NCT02858310,"Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, et al. TCR-Engineered T Cells Targeting E7 for Patients With Metastatic HPV-Associated Epithelial Cancers. Nat Med (2021) 27:419–25.doi: 10.1038/s41591-020-01225-1",_,_,_,_,_,_,3,33%,1,_,_,_,3,67%,2,_,_,_,6,50%,3
WT1,,,ENSG00000184937,TAA - overexpression,A*24:02,Human,Retroviral,——,Several sponsors,TAK-1 TCR,"AML, MDS",8,0,Transient decrease of blasts in BM in 2 pts.SD in 1 pt.," survival durations ranged from 2.7 to 39.4 months, with a median of 15.9 months",No adverse events greater than grade 3, 2×10^8-10×10^8/person,UMIN000011519,"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and Persistence of WT1-Specific T-Cell Receptor Gene–Transduced Lymphocytes in Patients With AML and MDS. Blood (2017) 130:1985–94. doi: 10.1182/BLOOD-2017-06-791202",,,,,,,,,,,,,,,,,,,,,
WT1,,,ENSG00000184937,TAA - overexpression,A*02:01,Human, lentiviral,High avidity,Fred Hutchinson CRC,TCRC4,AML (Post-HCT),12,_,100% RFS vs 54% in comparative group, a median follow-up of 44 months (range 21–57months),GVHD in several patients not likely caused by TCR T cells but rather HCT,——,NCT01640301,"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, et al.T Cell Receptor Gene Therapy Targeting WT1 Prevents Acute Myeloid Leukemia Relapse Post-Transplant. Nat Med (2019) 25:1064–72.doi: 10.1038/s41591-019-0472-9",,,,,,,,,,,,,,,,,,,,,
HBV,,,,Viral ,A*02:01,Human,——,——,,,hepatocellular carcinoma,8,12.5,"1/8 PR, 3/8SD, 2/8PD, 2/8NE",median overall survival was 14 months (range: 4 – 22 months),"Grade 3 alanine aminotransferase was elevated in 2/8pts, and grade 3 aspartate aminotransferase was elevated in 1/8pts",1×10^4-5×10^6/kg/person,NCT03899415,"Meng Fanping,Zhao Jinfang,Tan Anthony Tanoto et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.[J] .Hepatol Int, 2021, 15: 1402-1412.",,,,,,,,,,,,,,,,,,,,,
p53,,TP53,ENSG00000141510,TAA - overexpression,A*02,mice,Retroviral,——,,,"Breast, Melanoma, Esophageal Cancer",9,11,1/9PR,1month,None,5×10^8-110×10^9/person,NCT00562640,"Davis, J. L., Theoret, M. R., Zheng, Z. et al. 2010. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16:5852.",_,_,_,1,100%,1,3,0,0,2,0,0,4,0,0,6,33.30%,2,2,0,0
KRAS,G12D,,ENSG00000133703,Neoantigen,C*08:02,Human,Retroviral,____,NIH,,"Gastrointestinal cancer, colorectal cancer, pancreatic cancer",1,100,1/1ptsCR,Tumor regression lasted 35 months,None,1.11×10^11/person,NCT01174121,"Tran Eric,Robbins Paul F,Lu Yong-Chen et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.[J] .N Engl J Med, 2016, 375: 2255-2262.",_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,1,100%,1
KRAS,G12D,,ENSG00000133703,Neoantigen,C*08:02,Human,Retroviral,____,NIH,,"Gastrointestinal cancer, colorectal cancer, pancreatic cancer",2,50,"1/2pts tumor regression, 1/2pts tumor recurrence",176days,None,16.2×10^9/person,NCT03745326,"Leidner Rom,Sanjuan Silva Nelson,Huang Huayu et al. NeoantigenT-Cell Receptor Gene Therapy in Pancreatic Cancer.[J] .N Engl J Med, 2022, 386: 2112-2119.",_,_,_,_,_,_,_,_,_,_,_,_,2,50%,1,_,_,_,_,_,_
gp100,,PMEL,ENSG00000185664,TAA - differentation,HLA-A*0201,——,——,High,Immunocore,Tebentafusp,advanced melanoma,69,8.7,"The overall response rate (ORR) was 8.7% (6 responses, all partial responses; PR), with an additional 38 patients (55%) having stable disease, of which 5 patients (7.2%) exhibited mild disease responses","All patients achieved 65% overall survival at 1 year. The median duration of response was 10.5 months (range 3.7-28.2), and survival (censored at last exposure) was 33.4 months (range 13.9 to 47.2).",CRS,5 - 900 ng/kg,NCT01211262,"Middleton, Mark R et al. “Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,22 (2020): 5869-5878. doi:10.1158/1078-0432.CCR-20-1247",,,,,,,,,,,,,,,,,,,,,
gp100,,PMEL,ENSG00000185664,TAA - differentation,A02:01,mice,Retroviral,——,,,"Metastatic melanoma, skin cancer",3,33,1/3pts(PR)，0/3(CR),_____,1/3 pts intracranial hemorrhage; 1/3 pts hearing impairment; visual impairment,5×10^8-3×10^11/person,NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
MART-1,,MLANA,ENSG00000120215,TAA - differentation,A02:01,Human,Retroviral,——,,,"Metastatic melanoma, skin cancer",3,33,1/3pts(PR)，0/4(CR),_____,1/4 hearing impairment; visual impairment; 1/4 nervous system disorder,10^6-4×10^7/person,NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
MART-2,,,,TAA - overexpression,A02:01,Human,Retroviral,——,,,melanoma,,,——,——,——,2.3×10*10-13.7×10*10/person,NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human enhanced TCR, lentiviral,High,ADAP,C259 TCR,Metastatic melanoma ,11,18,"CR 2/11, PR 3/11",Two of the 11 melanoma patients showed complete regression that persisted after 1 year. ,No related toxicities,"a median of 5×10^10 T cells (range, 1.6 to 130 × 10^9)",,"Robbins Paul F,Morgan Richard A,Feldman Steven A et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.[J] .J Clin Oncol, 2011, 29: 917-24.",,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human enhanced TCR, lentiviral,High,ADAP,C259 TCR, metastatic synovial cell sarcoma,6,66.7,PR 4/6pts,Partial response lasting 18 months observed in one patient with synovial cell sarcoma,No related toxicities,"a median of 5×10^10 T cells (range, 1.6 to 130 × 10^9)",,"Robbins Paul F,Morgan Richard A,Feldman Steven A et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.[J] .J Clin Oncol, 2011, 29: 917-24.",,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human, lentiviral,——,,,ovarian cancer,,,_____,>4months,"1/6pts anemia, 2/6pts lymph node disease, 2/6 heart disease, 1/6 immune system disease",5×10^10/person,NCT01567891,CT Antigen TCR-redirected T Cells for Ovarian Cancer.（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human, lentiviral,High avidity,,,melanoma,,,1/4ptsPR，3/4died,——,"Fever in 1/4pts, disturbance of blood and lymphatic system in 2/4",5-10^10/person,NCT01350401,Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human, lentiviral,——,,,various solid tumors,,,"1/4 pts PR, 3/4 died",——,"Fever in 1/4pts, disturbance of blood and lymphatic system in 2/4",5-10^10/person,NCT02588612,Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,——,Retroviral,——,,,various solid tumors,,,8/11 (72.73%) died,>159days,"1/11pts heart disease, 1/11 blood system disorders, 1/11pts nervous system disorders, 1/11pts mental disorders, 1/11pts kidney and urinary system disorders",1×10^9-5×10^9/person,NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,mice,Retroviral,——,,,metastatic melanoma,2,,————,——,"1/2pts heart disease, 1/2pts breathing disorder, 2/2pts blood system disorder",1×10^9- 2×10^11/person,NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma（correponding article not reached）,,,,,,,,,,,,,,,,,,,,,
NY-ESO-1,,CTAG1B,ENSG00000184033,TAA - CT,A*02:01,Human, lentiviral,high affinity,Adaptimmune,NY-ESOc259,Multiple myeloma,20,,"nCR or CR 14/20,VGPR 2/20,PR 2/20,SD 1/20,PD 1/20",median OS has increased to 32.1 months,5 GvHD; 3 skin rash; 2 diarrhea; 1 hypotension,Average dose of 2.4×10^9/person,NCT01352286,"Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K. et al. 2015. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21:914.",,,,,,,,,,,,,,,,,,,,,
p53,,TP53,ENSG00000141510,TAA - overexpression,A*02:01,——,——,——,"NCI, Rosenberg",——,"Kidney cancer, melanoma",2,0,None,5 months,"2/2 pts disorders of the blood system; 2/2 pts disorders of the metabolic system; 1/2 pts disorders of the nervous system, breathing problems (1/2pts)",______,NCT00704938,"Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",,,,,,,,,,,,,,,,,,,,,
HPV E6; HPV E7,,,,Viral - HPV,——,——,——,——,"NCI, Rosenberg",,HPV-associated carcinomas,9,33.3,"2/9ptsPR,1/9ptsCR，6/9pts tumor progression","The duration of partial response was 3 months. Two complete response cases were maintained at 22 and 15 months after treatment, respectively",severe colitis ,"A median of 80×10^9 (range, 33 to 152×10^9)Tcells",NCT01585428,"Stevanović Sanja,Draper Lindsey M,Langhan Michelle M et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.[J] .J Clin Oncol, 2015, 33: 1543-50.",,,,,,,,,,,,,,,,,,,,,
MAGE-A1,,,ENSG00000198681,TAA - CT,A*02:01,Human natural TCR,Retroviral,Medium,Immatics,IMA201-101,,10,0,"Disease control in 7/10 patients (9 pts in DL1 & 2), no objective responses",,,,NCT03247309,,,,,,,,,,,,,,,,,,,,,,
PRAME,,,ENSG00000185686,TAA - CT,A*02:01,Human enhanced TCR,Retroviral,High,Immatics,IMA203,"Melanoma,Head & Neck Cancer,Synovial Sarcoma",16,50,"Objective responses in 8/16 patients, thereof 8/13 responses above DL1",_,Most frequent TEAEs included expected transient cytopenia (Grade 1-4) associated with lymphodepletion and transient low to moderate (Grade 1-2) cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS),1×10^9/person,NCT03686124,"The objective of the Phase 1 clinical trials with the ACTengine® product candidates, IMA201 IMA203 and IMA203CD8 is to evaluate safety, tolerability and initial signs of clinical and biological efficacy in target-positive solid cancer patients. The clinical trials continue to actively recruit patients.",,,,,,,,,,,,,,,,,,,,,
AFP,,,ENSG00000081051,TAA - CT,e HLA-A*02:01 or HLA-A*02:642,genetically engineered affinity-enhanced,Retroviral,affinity-enhanced,ADAP,ADP-A2AFP, HCC,13,7.60%,"1/11, 7.6% (ORR/CR)",32weeks,Febrile neutropenia; Cytokine release syndrome; Back pain,1×10^8-5×10^9/person,NCT03132792,"Initial safety of AFP SPEAR T-Cells in patients with advanced hepatocellular carcinoma. PDF poster. AACR Annual Meeting. Mar. 29-Apr. 3, 2019. Atlanta, GA. Lipika Goyal, MD, et al.",_,_,_,_,_,_,2,0,0,_,_,_,_,_,_,_,_,_,_,_,_